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Abstract 
Background: Because type 2 diabetes mellitus is associated strongly with an increased risk of cardiovascular dis‑
eases, the number of patients with diabetes with chronic heart failure is increasing steadily. However, clinical evidence 
of therapeutic strategies in such patients is still lacking. A recent randomized, placebo‑controlled trial in patients 
with type 2 diabetes with high cardiovascular risk demonstrated that the SGLT2 inhibitor, empagliflozin, reduced the 
incidence of hospitalization for heart failure. Because SGLT2 inhibitors cause a reduction in body weight and blood 
pressure in addition to improving glycemic control, they have the potential to exert beneficial effects on the clinical 
pathophysiology of heart failure. The aim of the ongoing CANDLE trial is to test the safety and non‑inferiority of cana‑
gliflozin, another SGLT2 inhibitor, compared with glimepiride, a sulfonylurea agent, in patients with type 2 diabetes 
mellitus and chronic heart failure.
Methods: A total of 250 patients with type 2 diabetes who are drug‑naïve or taking any anti‑diabetic agents and 
suffering from chronic heart failure with a New York Heart Association classification I to III will be randomized cen‑
trally into either canagliflozin or glimepiride groups (1: 1) using the dynamic allocation method stratified by age 
(<65, ≥65 year), HbA1c level (<6.5, ≥6.5 %), and left ventricular ejection fraction (<40, ≥40 %). After randomization, 
all the participants will be given the add‑on study drug for 24 weeks in addition to their background therapy. The pri‑
mary endpoint is the percentage change from baseline in NT‑proBNP after 24 weeks of treatment. The key secondary 
endpoints after 24 weeks of treatment are the change from baseline in glycemic control, blood pressure, body weight, 
lipid profile, quality of life score related to heart failure, and cardiac and renal function.
Discussion: The CANDLE trial is the first to assess the safety and non‑inferiority of canagliflozin in comparison with 
glimepiride in patients with type 2 diabetes with chronic heart failure. This trial has the potential to evaluate the clini‑
cal safety and efficacy of canagliflozin on heart failure.
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Background
Co-morbidities associated with type 2 diabetes mellitus 
(T2DM) are increasing steadily in patients with chronic 
heart failure (CHF). Their prevalence was reported to be 
30 % in the JCARE-CARD trial and 23 % in the CHART-2 
trial [1, 2]. Complications of T2DM aggravate clini-
cal outcomes, such as higher mortality, morbidity, and 
re-hospitalization rate for worsening heart failure in 
patients with CHF. This indicates that T2DM is a rela-
tively strong risk factor for CHF [3, 4]. Although glycemic 
control is recognized as essential, a U-curve phenom-
enon is found between HbA1c levels and mortality in 
CHF patients with T2DM [5]. The treatment guidelines 
for CHF of the Japanese Circulation Society are similar to 
those of the American Heart Association and European 
Society of Cardiology in that the established evidence on 
the recommended therapeutic strategies in T2DM are 
not provided [6]. In addition, the Japan Diabetes Soci-
ety has also not described specific treatment options for 
diabetes in patients with CHF, although lowering HbA1c 
levels to <7.0 % is recommended in order to suppress the 
development and progression of microvascular compli-
cations [7].
Sodium glucose co-transporter 2 (SGLT2) inhibi-
tors are a novel class of anti-diabetic agents that have 
a blood glucose-lowering effect by increasing urinary 
glucose excretion [8, 9]. In addition to this glucose-low-
ering effect, previous studies have demonstrated that 
SGLT2 inhibitors decrease blood pressure (BP) due to 
their osmotic diuretic action, and also induce meta-
bolic ameliorations, including a reduction of visceral fat 
and body weight (BW) [10–12]. The diuretic action of 
SGLT2 inhibitors may also have advantages on heart fail-
ure. Recently, it has been reported that administration of 
empagliflozin, a SGLT2 inhibitor, as an add-on to conven-
tional anti-diabetic therapy, significantly reduced cardio-
vascular (CV) adverse outcomes in T2DM patients with 
higher CV risk [13]. Given their pleiotropic pharmaco-
logical actions, SGLT2 inhibitors appear to contribute to 
amelioration of the clinical course of T2DM patients with 
CHF by reducing both blood glucose and excess body 
fluid. Canagliflozin is another SGLT2 inhibitor and the 
first-in-class drug launched in the United States. In phase 
III clinical trials, canagliflozin was reported to cause 
favorable long-term glycemic and metabolic improve-
ment and was well tolerated as either mono-therapy or 
in combination with other anti-diabetic agents [14–16]. 
Another randomized placebo-controlled trial designed 
to assess the longer-term effects of canagliflozin on clini-
cal outcomes in T2DM patients is currently being carried 
out [17]. To enhance the favorable class effect of SGLT2 
inhibitors on cardiovascular events, it is important to 
refer to additional trials on other SGLT2 inhibitors. 
However, T2DM patients with severe CHF with a New 
York Heart Association (NYHA) functional classification 
of III and IV were excluded from these trials, because the 
use of SGLT2 inhibitors is not clinically recommended in 
these patients. As a consequence, the clinical efficacy and 
safety of SGLT2 inhibitors in T2DM patients with CHF 
remains to be elucidated (Fig. 1).
The CANDLE trial was designed to test the safety and 
non-inferiority of canagliflozin, compared with glime-
piride, using N-terminal pro-brain natriuretic peptide 
(NT-proBNP) as the index of the therapeutic effects in 
T2DM patients with CHF. This trial has the potential to 
provide novel clinical evidence regarding the safety and 




The CANDLE trial is an ongoing, multicenter, prospec-
tive, randomized, open-label, blinded-endpoint investiga-
tor-initiated clinical trial. This study tests the hypothesis 
that additional administration of canagliflozin to stand-
ard therapy does not worsen the pathological state of 
CHF, compared to the conventional anti-diabetic agent, 
glimepiride. Twenty-four weeks after recruitment and 
randomization into either canagliflozin or glimepiride 
groups, the safety and non-inferiority of canagliflozin for 
T2DM patients with CHF will be evaluated using NT-
proBNP as a biomarker of heart failure.
Prior to initiation, the study protocol needs to be 
approved by the local institutional review boards and 
independent ethics committees at every site. The trial 
will be conducted in full compliance with the Declaration 
of Helsinki and according to the Ethical Guidelines for 
Medical and Health Research Involving Human Subjects 
established by the Ministry of Health, Labour, and Wel-
fare and Ministry of Education, Culture, Sports, Science, 
and Technology.
Trial population and recruitment
We aim to recruit a total of 250 participants across 
approximately 35 sites in Japan. Recruitment for this trial 
began in October 2015 and will be completed by Decem-
ber 2017. Eligible patients in the trial are T2DM patients 
with CHF (aged  ≥20  years) who comply with all the 
enrollment criteria. The detailed inclusion and exclusion 
criteria are listed in Table 1. Briefly these criteria include: 
(1) Patients with appropriately diagnosed T2DM, who 
are drug-naïve or taking any anti-diabetic agent; (2) 
T2DM clinically requiring a start or change of an anti-
diabetic agent; (3) complicating NYHA functional classi-
fication I to III CHF, but not IV, with maintenance of the 
clinical condition and unchanged medical treatment for 
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CHF, including angiotensin-converting enzyme inhibi-
tors, angiotensin II receptor blockers, beta-blockers, and 
diuretic agents for 4 weeks prior to screening. In the trial, 
CHF is classified comprehensively by skilled cardiolo-
gists using several findings, including clinical symptoms 
(the Framingham criteria for congestive heart failure and 
NYHA functional classification), history of hospitaliza-
tion for heart failure, and clinical tests such as echocardi-
ography and biomarkers. However, there is no limitation 
on the NT-proBNP level at enrollment. Prior to eligibil-
ity screening, every participant is required to receive an 
adequate explanation based of the trial plan, with written 
informed consent then being obtained from each patient.
Trial outline and follow‑up
After informed consent has been provided and the eligi-
bility assessment completed, all eligible participants will 
be randomized and assigned into either the canagliflozin 
or glimepiride groups. Post-randomized follow-up visits 
are scheduled at 4, 12, and 24 weeks (Fig. 2). All partici-
pants will see their usual-care physicians at each visit to 
receive usual-care and individualized appropriate treat-
ment according to their background disease, T2DM, and 
CHF, in addition to administration of the study drug.
Randomization and treatment
Eligible patients with the appropriately signed informed 
consent will be randomized to either the canagliflozin or 
glimepiride groups at a ratio of 1:1 using the minimiza-
tion method with biased coin assignment balancing for 
age (<65,  ≥65  year), HbA1c level (<6.5,  ≥6.5  %), and 
left ventricular ejection fraction (LVEF;  <40,  ≥40  %) at 
the time of screening [18, 19]. The trial is an open-label 
design, although the assessor(s) will be blinded to treat-
ment randomization. The assessors will also be blinded 
to the primary end point, NT-proBNP level, by measure-
ment at a central laboratory.
All participants receive the study drug for 24  weeks. 
Patients who are assigned to the canagliflozin group 
receive canagliflozin 100 mg once daily. The EMPA-REG 
OUTCOME trial reported small dose-dependent effects 
of empagliflozin (10  mg vs. 25  mg/day) on metabolic 
parameters. However, the two dose groups had similar 
hazard ratios for cardiovascular outcomes [13]. Some 
studies on canagliflozin showed that 100 mg/day had suf-
ficient effects on metabolic parameters, while 300 mg/day 
was slightly more effective [14, 15, 20]. Importantly, only 
100 mg/day is approved in Japan, and therefore the dose 
of canagliflozin is fixed at 100 mg/day in the canagliflo-
zin group. Because of the possible risk of excess diuresis 
and subsequent dehydration by combined use of canagli-
flozin and diuretics, the dose of the diuretics may need 
to be reduced when necessary. Patients assigned to the 
glimepiride group are started at a dose of 0.5 or 1.0 mg 
once or twice daily. According to the individual’s glyce-
mic control, the dose of glimepiride can be increased to 
6.0 mg/day. For background therapy in both groups, par-
ticipants who have been receiving any SGLT2 inhibitor 
other than canagliflozin need to discontinue it at the start 
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Fig. 1 Trial concept. Conventional diuretics are well established agents for CHF. On the other hand, SGLT2 inhibitors are new anti‑diabetic agents 
with multiple favorable effects such as improving glycemic and metabolic parameters. In addition, empagliflozin has recently been reported to 
reduce the risk of CV events asterisk [13]. However, the beneficial effects of SGLT2 inhibitors in T2DM patients with CHF have yet to be established. 
BP blood pressure, BW body weight, CHF chronic heart failure, CV cardiovascular, SGLT2 sodium glucose cotransporter 2, T2DM type 2 diabetes mel‑
litus
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study drug, canagliflozin or glimepiride. While, partici-
pants who have been taking a sulfonylurea need to stop 
taking it in the canagliflozin group and need to change 
to glimepiride (if needed) in the glimepiride group at the 
initiation of the study drug (Additional file 1). Because of 
the possible risk of excess diuresis and subsequent dehy-
dration by combined use of canagliflozin and diuretics, 
the dose of the diuretics may need to be reduced when 
necessary.
Although a specific numerical goal of HbA1c level is 
not set in this trial, all participants need to be treated to 
achieve a personalized goal recommended by the guide-
lines (details in Additional file 2) [7]. Drugs that must not 
be used in combination with the study drugs are listed in 
Table  2. Within the appropriate range of the therapeu-
tic goal, the participant’s background treatment will be, 
in principle and if possible, unchanged during the trial 
interval. If participants cannot achieve their glycemic 
goal, co-administration of anti-diabetic agents other than 
SGLT2 inhibitors and sulfonylureas or increased dosages 
of the anti-diabetic agents other than the target agents in 
both groups may be initiated, with caution being taken 
to prevent the development of hypoglycemia. After the 
trial is completed, all participants can continue any anti-
diabetic treatment in accordance with their individual 
condition.
Measurements
Baseline characteristics, including smoking habit, NYHA 
functional classification, etiology of CHF, hypertension, 
dyslipidemia, and other complications will be screened 
prior to randomization. The medication status of the 
study agents, and the participant’s background treat-
ment, BW, BP, and heart rate will be also measured at 
each visit. A chest X-ray is taken at baseline and at the 
final visit. An echocardiogram is performed at screen-
ing, baseline, and the final visit to measure LVEF using 
the modified Simpson method and E/e’. The echocardio-
grams will be evaluated by technicians at each local site. 
Blood and urine tests will be checked at each visit (details 
listed in Additional file 3). Specific biomarkers, including 
NT-proBNP, high-sensitivity C reactive protein (hsCRP), 
serum cystatin C, pentraxin 3 (PTX3) (SRL, Inc. Tokyo, 
Japan), high-sensitivity troponin I (Abbot Japan, Tokyo, 
Japan), receptor for advanced glycation end prod-
ucts (RAGE), angiopoietin-like protein 2 (ANGPTL2), 
Table 1 Detailed inclusion and exclusion criteria
ALT alanine aminotransferase, AST aspartate transaminase, BMI body mass index, CHF chronic heart failure, eGFR estimated glomerular filtration rate, NYHA New York 
Heart Association, SGLT2 sodium glucose cotransporter 2, T2DM type 2 diabetes mellitus
Inclusion Exclusion
Adults (aged ≥20 years) Type 1 diabetes mellitus
T2DM patients who need to start or who are possibly changing or adding 
an anti‑diabetic agent
History of diabetic ketoacidosis, diabetic coma, or hypoglycemic 
attack ≤6 months prior to informed consent
CHF (NYHA functional classification I to III) Severe renal dysfunction (eGFR <45 ml/min/1.73 m2) or patients receiving 
dialysis
Without change in NYHA functional classification or drugs for heart failure 
4 weeks prior to eligibility
Severe liver dysfunction (at least threefold higher AST or ALT more than the 
upper limit of the facilities reference value
The patient provided written informed consent to participate in the study CHF (NYHA functional classification IV)
Patients with pituitary or adrenal dysfunction
Patients with malnutrition, starvation, irregular eating pattern, lack of 
dietary intake, or debilitation
Patients with excess alcohol intake
Patients in perioperative period around trial screening
Patients with severe infection or trauma at trial screening
Patients with a gastrointestinal disorder, such as diarrhea or vomiting
Patients with low body weight (BMI <18.5 kg/m2)
History of coronary artery disease, coronary vascularization, open‑heart 
surgery, stroke, or transient ischemic attack ≤3 months prior to eligibility
Patients with a malignancy
History of hypersensitivity to ingredients of SGLT2 inhibitors or sulfonylu‑
reas
Pregnant or suspected pregnancy in females
Lactating female
Considered inappropriate for the study by investigators due to other 
reasons
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interleukin 8 (IL-8), and periostin (Saga University) will 
be measured at a central laboratory at baseline and the 
final visit. CHF-related quality of life is evaluated by 
scaled responses to the Minnesota Living with Heart 
Failure (MLHF) questionnaire at baseline and the final 
visit. The occurrence of CV events, including all-cause 
death, non-fatal myocardial infarction, non-fatal stroke, 
hospitalization for heart failure, and additional medica-
tions or dosage increases of drugs due to aggravation of 
heart failure will be evaluated.
Safety
Based on the intention-to-treat entire population, safety 
will be checked by recording the following adverse 
effects throughout the duration of the study: hypo-
glycemia, genital infections, urinary tract infections, 
excess osmotic diuresis signs (increased urinary fre-
quency, mouth dryness, or polyuria), and hypovolemic 
symptoms. A previous study has reported an increased 
prevalence of hypoglycemia with sulfonylureas than 
with canagliflozin [14]. We therefore need to pay care-
ful attention to the development of hypoglycemia, espe-
cially in patients assigned to the glimepiride group, 
despite this drug being initiated at a low dose in the 
study. If the investigators confirm these adverse effects, 
the grade of severity, treatment, outcomes, and relation-
ship to the study drug will be assessed. The criteria for 
withdrawal from the trial are listed in Table 3. In addi-
tion, the incident of withdrawal from the study will be 
reported promptly to the Data and Safety Monitoring 
Board (DSMB) by the trial organizer.
Trial endpoints
NT-proBNP is used widely to monitor the therapeutic 
efficacy of agents for heart failure in clinical trials and is 
established as a prognostic biomarker for heart failure 
[21–23]. In addition, NT-proBNP-guided treatment for 
heart failure has been demonstrated to improve clini-
cal outcomes in a randomized trial [24]. Therefore, the 
percent change in NT-proBNP levels from baseline to 
24  weeks will be used as the primary endpoint in the 











Background therapy for heart failure, diabetes, and other condions
Fig. 2 Trial outline
Table 2 Prohibited concomitant drugs
SGLT2 sodium glucose cotransporter 2
Canagliflozin group




 Sulfonylureas other than glimepiride
 SGLT2 inhibitors
 Pioglitazone
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CANDLE trial. The secondary endpoints are the values 
and changes in parameters after 24  weeks of treatment 
(or at discontinuation), including: (1) NT-proBNP, (2) 
glycemic control (HbA1c, fasting plasma glucose, plasma 
insulin, HOMA-R and HOMA-beta), (3) clinic systolic 
and diastolic BP and home BP (optional), (4) BW, (5) bio-
chemical tests (lipid profiles and uric acid), (6) quality of 
life (MLHF scores) (7) echocardiographic cardiac func-
tion parameters (LVEF and E/e’) and severity and change 
in NYHA functional classification, and (8) renal func-
tion parameters (serum creatinine level, estimated glo-
merular filtration rate (eGFR), urinary albumin excretion, 
and urine L-FABP). Other secondary endpoints include 
clinical outcomes such as CV events, including all-cause 
death, non-fatal myocardial infarction, non-fatal stroke, 
hospitalization for heart failure, and changes in medica-
tions related to aggravation of heart failure. Safety end-
points include adverse effects and adverse drug reactions 
observed during treatment with the study drugs. The 
exploratory endpoints are changes in specific biomark-
ers after 24 weeks of treatment, including high-sensitiv-
ity troponin I, hsCRP, serum cystatin C, PTX3, RAGE, 
ANGPTL2, IL-8, and periostin. The findings of these bio-
marker assays may, in part, provide mechanistic insights 
on the effect of canagliflozin on CV pathogenesis.
Endpoint adjudication
A clinical event committee (CEC) blinded to treat-
ment allocation will independently adjudicate the clini-
cal events. The DSMB blinded to treatment allocation 
will also independently evaluate safety during the study 
period. The DSMB will also assess the necessity for revi-
sion of the trial design and the validity for continuance of 
trial entry, and if needed, recommend issues for the chief 
investigator. The members of the CEC and DSMB consist 




Due to the lack of data on the effect of SGLT2 inhibitors, 
including canagliflozin, on NT-proBNP levels, we used 
data from the PARAMOUNT study on CHF patients 
with preserved ejection fraction [25]. That study used 
the same primary end point to compare the efficacy and 
safety of LCZ696, an angiotensin receptor neprilysin 
inhibitor, with valsartan. On the basis of the findings of 
that study, we assumed an 18 % difference in NT-proBNP 
reduction between the two groups in our trial. In detail, 
estimation of the sample size for the CANDLE trial was 
based on the percentage change from baseline to the final 
NT-proBNP level, required to demonstrate non-inferior-
ity of canagliflozin versus glimepiride, using a one-sided 
Student t test with a 2.5 % type I error. In this calculation 
we assumed that for a common standard deviation for 
the log-scale of the ratio of 0.80, a clinical non-inferiority 
margin of 1.1, and a dropout rate of 10 %, it was neces-
sary to recruit 125 patients in each group in the full anal-
ysis set (FAS) to demonstrate non-inferiority if the true 
difference was 18 % and the power was at least 80 %.
Analysis plan
The analyses of the primary and secondary endpoints will 
be performed in the FAS, which includes all patients who 
received at least one dose of treatment during the study 
period and did not have any serious violation of the study 
protocol, and had data collected after commencement 
of treatment. For the baseline characteristics, the sum-
mary statistics will comprise frequencies and proportions 
for categorical variables, and means and standard devia-
tions for continuous variables. The patient characteristics 
will be compared using Chi square tests for categorical 
variables, and t tests for normally distributed continuous 
variables or Wilcoxon rank sum tests for continuous vari-
ables with a skewed distribution.
For the primary analysis comparing treatment effects, 
the least square mean and its 95  % confidence interval 
will be estimated using analysis of covariance (ANCOVA). 
To test for non-inferiority of the primary endpoint, the 
ANCOVA will be applied adjusted for age (<65, ≥65 year), 
HbA1c level (<6.5, ≥6.5  %), and left ventricular ejection 
fraction (LVEF; <40, ≥40 %). The secondary analysis will 
be performed in the same manner as the primary analysis.
All comparisons are planned and all p values will be 
two sided. P values <0.05 will be considered statistically 
significant. All statistical analyses will be performed 
using SAS software version 9.4 (SAS Institute, Cary, NC, 
USA). The statistical analysis plan will be developed by 
the principal investigator and a biostatistician before 
completion of patient recruitment and database lock.
Table 3 Discontinuance criteria
Severe hypoglycemia that needs some support by family members or 
medical care at medical settings
Seriously poor glycemic control such as ≥HbA1c 10.0 %
Diabetic ketoacidosis
Dehydration
Considered inappropriate to continue the study by investigators due to 
aggravation of primary disease or complications
Considered inappropriate to continue the study by investigators due to 
adverse side effects of the study drug
Offer for participation declined by participants
Considered inappropriate to continue the study by investigators due to 
some other reason
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Trial organization and oversight (details in Additional 
file 4).
Principal investigators of the CANDLE trial are Koichi 
Node (Chief ), Department of Cardiovascular Medicine, 
Saga University and Toyoaki Murohara, Department of 
Cardiology, Nagoya University Graduate School of Medi-
cine. The Steering Committee will carry out planning, 
operating, analyzing, and presentation of the trial. The 
Executive Committee will supervise the trial design and 
operation of the study. The roles of DSMB and CEC are 
described in the section of Endpoint adjudication. The 
trial secretariat is in DOT INTERNATIONAL CO., LTD, 
Tokyo, Japan. Each of data management, monitoring, sta-
tistical analyses, and audit will be independently imple-
mented on the basis of outsourcing agreement.
Discussion
The CANDLE trial is an ongoing, multicenter, prospec-
tive, randomized, investigator-initiated clinical trial that 
has the aim of testing the safety and non-inferiority of 
canagliflozin in T2DM patients with CHF. In this trial, 
eligible participants will be randomized to canagliflozin 
or glimepiride groups and receive the study drug in addi-
tion to their background medications for 24 weeks. The 
primary endpoint is the percentage change from baseline 
in NT-prBNP level after 24 weeks of treatment. This trial 
has the potential to generate novel evidence regarding 
the clinical relevancy of canagliflozin in T2DM patients 
with CHF.
Accumulating evidence suggests that T2DM has a 
major impact on the increased risk of micro- and macro-
vascular complications that are associated strongly with 
unfavorable clinical outcomes and poor prognosis [26–
29]. Importantly, comprehensive medical intervention in 
diabetic management is encouraged at earlier stages of 
disease development in order to improve patient progno-
sis [30–32]. Although previous studies have shown that 
glucose-lowering therapy is important in the clinical set-
ting, the beneficial effects on long-term outcomes and 
prognosis remain controversial [33–37]. For the man-
agement of diabetic patients, current guidelines state 
therapeutic goals for HbA1c levels, based on the patient’s 
background and tolerability to treatment [7]. In addition, 
for safety reasons it is essential that anti-diabetic agents 
do not increase the risk of CV events, and at least, are 
not inferior to conventional therapy [38]. Nevertheless, 
despite the increasing number of T2DM patients com-
plicated with CHF, in whom a higher risk of CV events 
is possible, there is no clinical evidence on therapeu-
tic goals based on safety and efficacy in this population. 
Therefore, establishment of therapeutic guidelines for 
T2DM patients with CHF is required.
Of the various conventional anti-diabetic agents, thia-
zolidine derivatives are effective for improving insulin 
resistance by enhancing insulin sensitivity in peripheral 
tissues, but need to be administered with caution because 
of possible adverse effects such as worsening of edema 
and heart failure [39, 40]. Dipeptidyl peptitadase-4 inhib-
itors have been shown to have neutral effects on CV out-
come in both the EXAMINE (alogliptin vs. placebo) and 
TECOS (sitagliptin vs. placebo) trials [41, 42]. However, 
the SAVOR-TIMI53 trial (saxagliptin vs. placebo) dem-
onstrated recently a significantly higher incidence of 
hospitalization for heart failure in the saxagliptin group, 
compared to placebo [43]. Therefore, at present the clini-
cal use of anti-diabetic agents in T2DM patients with 
CHF is, in part, somewhat limited. As a consequence, 
although these patients are considered to be at higher 
CV risk and require more effective treatment strategies 
to improve their clinical outcome, no specific treatment 
guidelines have been established. Metformin is recog-
nized widely as the first line strategy for treatment of 
type 2 diabetes in the USA and Europe, with some study 
showing a preference for metformin over sulfonylureas 
in diabetes patients with heart failure [44, 45]. How-
ever, metformin is not necessarily a first line treatment 
option in Japan [7]. Although the present study excludes 
patients with renal dysfunction who are prohibited to 
receive metformin, metformin is contraindicated in 
Japan for patients with heart failure because of the risk 
of lactic acidosis. In addition, it has been reported that 
decreased insulin secretion capacity has a pivotal role 
in the development of T2DM in Japanese subjects and 
accordingly sulfonylureas are used more frequently than 
metformin in Japan [46]. To our knowledge, there is no 
direct evidence showing that sulfonylureas increase the 
risk of heart failure. A phase III trial in the USA showed 
sulfonylureas had similar power to decrease HbA1c levels 
as canagliflozin 100  mg/day [14]. We therefore selected 
glimepiride as the comparison agent.
Previous clinical trials in T2DM patients demonstrated 
that SGLT2 inhibitors are well tolerated by patients and 
exert favorable effects on BP and systemic metabolisms 
such as body fat loss, in addition to improving glycemic 
control [10–12]. Experimental studies using animal mod-
els have shown that SGLT2 inhibitors also reduce inflam-
mation and oxidative stress in hepatic, renal, and cardiac 
tissues [47–50], and therefore presumably would have a 
protective effect on the CV system. These class effects 
would be expected to be highly advantageous for dia-
betic patients with increased CV risk, while the diuretic 
effects of SGLT2 inhibitors may also be potentially effec-
tive in CHF patients who require frequent administration 
of diuretic agents. However, there is no evidence clinical 
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evidence on the clinical safety of SGLT2 inhibitors for 
heart failure, and it is possible excess intravascular fluid 
depletion may be exacerbated following administra-
tion of SGLT2 in patients with heart failure taking diu-
retics. Given this current status, it is necessary to assess 
the safety and efficacy of SGLT2 inhibitors for diabetic 
patients with CHF.
The results of the EMPA-REG OUTCOME trial 
showed that administration of empagliflozin significantly 
reduced CV adverse outcomes in T2DM patients with 
higher CV risk [13]. Compared to the placebo group, 
any cause of death including worsening of heart failure, 
was significantly lower in the empagliflozin group. In 
addition, a 35  % relative risk reduction in hospitaliza-
tion for heart failure was observed in the empagliflozin 
group. Although a significant reduction in hospitalization 
for heart failure was clearly documented, participants 
with heart failure comprised only about 10 % of the trial 
population at baseline. Moreover, about 40 % of the par-
ticipants were taking diuretics at baseline, and therefore 
how to use SGLT2 inhibitors in conjunction with diuret-
ics was of great concern in the clinical management of 
these patients. Taken together, the therapeutic effects of 
SGLT2 inhibitors in specific patients with heart failure 
have yet to be established (Fig. 1). It is therefore neces-
sary to assess the clinical safety and efficacy of SGLT2 
inhibitors focusing on T2DM patients with CHF.
Among the SGLT family, SGLT2 plays a central role in 
glucose reuptake specifically in the proximal renal tubule 
with high-capacity and low-affinity. SGLT1 is also a glu-
cose transporter with low-capacity and high-affinity and 
is expressed mainly in the intestine, kidney, and heart. 
Compared with other SGLT2 inhibitors, canagliflozin has 
a relatively lower selectivity for SGLT2 over SGLT1 [51], 
and as a result also inhibits SGLT1 in the upper intestine, 
causing a delayed postprandial hyperglycemic response, 
similar to that seen with alpha-glucosidase inhibitors 
[52]. In addition, intestinal SGLT1 inhibition enhances 
glucagon-like peptide-1 secretion from L-cells in the 
lower intestine where residual glucose may reach [53]. 
Based on these results, simultaneous inhibition of SGLT1 
by canagliflozin may also contribute, in part, to treatment 
of T2DM, despite its possible gastrointestinal side effects 
such as diarrhea caused by glucose-galactose malabsorp-
tion. However, the potential impacts of SGLT1 inhibition 
by canagliflozin on heart tissue still remain uncertain, 
due to the high blood protein-binding of canagliflozin of 
about 99 %. Cardiac SGLT1 is highly expressed in myo-
cyte salcolemma and significantly up-regulated accord-
ing to the pathological condition of cardiomyocytes with 
altered glucose requirements that occurs in diabetic 
or ischemic cardiomyopathy and in failing hearts [54]. 
Because the expression level of cardiac SGLT1 correlates 
with cardiac pathogenesis, inhibitors of the SGLT family 
may exert favorable effects on cardiac diseases [55]. On 
the other hand, studies in mouse models of ischemia–
reperfusion injury have shown cardiac SGLT1 may have 
a cardioprotective role by optimizing glucose uptake into 
heart tissue [56]. Further in vitro and in vivo studies are 
needed to determine the clinical effects of canagliflozin 
on cardiac SGLT1 inhibition.
There are several limitations in the trial. First, the CAN-
DLE trial is not a placebo-controlled trial. The aim of 
the trial is therefore to test the safety and non-inferiority 
of canagliflozin compared with glimepiride in T2DM 
patients with CHF. Second, as the trial is an open label 
design, there may be some bias towards the assessment of 
outcomes resulting from the physicians’ choice of treat-
ment. However, there are strict definitions on the back-
ground treatment that will, in principle and if possible, 
remain unchanged during the trial interval. To overcome 
this possible bias, NT-proBNP, a primary endpoint, will be 
measured at a central laboratory, and all the data will be 
managed and statistically analyzed in a blinded manner. 
Finally, the trial interval of 24 weeks may be short to titrate 
the appropriate dose of glimepiride. According to a pre-
vious study from Japan that evaluated the safety and effi-
cacy of glimepiride titration using self-monitoring blood 
glucose (SMBG) method [57], glimepiride treatment dur-
ing 24 weeks resulted in a sufficient reduction in HbA1c 
level in the SMBG group and even in patients in the con-
trol group who were titrated empirically by their clinician 
without causing severe hypoglycemia. The average doses 
of glimepiride were 1.0 ± 0.8 mg/day in the SMBG group 
and 0.6 ± 0.3 mg/day in the control group, with no patient 
receiving glimepiride ≥3.5 mg/day. In addition, the HbA1c 
level at 24 weeks was significantly lower in patients receiv-
ing 0.5 mg/day compared with patients receiving >0.5 mg/
day. This result indicates that glimepiride treatment for 
24 weeks may not necessarily be too short to titrate glime-
piride. Inappropriate titration of glimepiride may impact 
glycemic control and NT-proBNP levels in the glimepiride 
group, although there is currently insufficient evidence, as 
to whether or not, or the extent to which glimepiride treat-
ment may affect NT-proBNP levels.
In summary, accumulated evidence suggests that 
SGLT2 inhibitors may have considerable impact on clini-
cal diabetes care, with the potential to markedly improve 
clinical outcomes in patients with T2DM, especially 
those at higher risk of CV events. It is therefore impor-
tant to evaluate the clinical implication of SGLT2 inhibi-
tors in T2DM patients with CHF. The CANDLE trial is 
the first to test the safety and non-inferiority of canagli-
flozin for T2DM patients with CHF. This study has the 
potential to provide novel clinical insights on the treat-
ment of diabetic patients with high CV risk.
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